A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition

被引:86
作者
Castro-Perez, J
Plumb, R
Liang, L
Yang, E
机构
[1] Waters Corp MS Technol Ctr, Manchester M23 9LZ, Lancs, England
[2] Waters Corp, Milford, MA 01757 USA
[3] GlaxoSmithKline, Drug Metab & Pharmacokinet, World Bioanal, King Of Prussia, PA 19406 USA
关键词
D O I
10.1002/rcm.1855
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Chemically reactive metabolites may cause hepatotoxicity and as a result liver failure or other adverse side reactions. Therefore, this is a vital topic of interest because early reactive metabolite screening may prevent compound failure at a later stage. In order to address this issue, a screening assay has been developed to detect the formation of reactive metabolites by using glutathione as a trapping reagent, which will allow us to search for phase I metabolites and also glutathiones during in vitro metabolite screening using liquid chromatography/tandem mass spectrometry (LC/MS/MS) with exact mass. Glutathione conjugations when fragmented by the mass spectrometer give a common loss corresponding to the pyroglutamic acid moiety, which can be monitored. Until recently, this work has been carried out with triple quadrupole technology using nominal mass. The advantage of the hybrid quadrupole time-of-flight mass spectrometer is the selectivity and sensitivity that can be achieved. Exact neutral loss detection is achieved via sequential low- and high-energy MS acquisitions. After detection of the loss of the pyroglutamic acid moiety, using a window of +/- 20 mDa on the high-energy scan, MS/MS is carried out on the parent mass of interest to confirm the common neutral loss. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:798 / 804
页数:7
相关论文
共 24 条
[1]
Baillie TA, 2001, ADV EXP MED BIOL, V500, P45
[2]
MASS-SPECTROMETRY IN THE ANALYSIS OF GLUTATHIONE CONJUGATES [J].
BAILLIE, TA ;
DAVIS, MR .
BIOLOGICAL MASS SPECTROMETRY, 1993, 22 (06) :319-325
[3]
PROTOCOL FOR LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY OF GLUTATHIONE CONJUGATES USING POSTCOLUMN SOLVENT MODIFICATION [J].
BEAN, MF ;
PALLANTEMORELL, SL ;
DULIK, DM ;
FENSELAU, C .
ANALYTICAL CHEMISTRY, 1990, 62 (02) :121-124
[4]
Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation [J].
Chen, Q ;
Ngui, JS ;
Doss, GA ;
Wang, RW ;
Cai, XX ;
DiNinno, FP ;
Blizzard, TA ;
Hammond, ML ;
Stearns, RA ;
Evans, DC ;
Baillie, TA ;
Tang, W .
CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (07) :907-914
[5]
Chen WCG, 2001, ADV EXP MED BIOL, V500, P521
[6]
CUNEYT G, 2004, CURR TOP MED CHEM, V4, P1409
[7]
Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development [J].
Evans, DC ;
Watt, AP ;
Nicoll-Griffith, DA ;
Baillie, TA .
CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (01) :3-16
[8]
HAROLDSEN DE, 1988, BIOMED ENVIRON MASS, V17, P615
[9]
OFF-LINE LIQUID-CHROMATOGRAPHIC FAST ATOM BOMBARDMENT TANDEM MASS-SPECTROMETRIC ANALYSIS OF TWO DIASTEREOMERIC GLUTATHIONE CONJUGATES OF ALPHA-BROMOISOVALERYL UREA [J].
HEEREMANS, CEM ;
TEKOPPELE, JM ;
NIESSEN, WMA ;
VANDERGREEF, J ;
BRUSSEE, J ;
LAVOS, GF ;
DEBRAUW, MCT ;
VANDERGREEF, J .
BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1988, 17 (03) :181-186
[10]
Kalgutkar Amit S., 2002, Current Drug Metabolism, V3, P379, DOI 10.2174/1389200023337360